Page last updated: 2024-08-05 11:55:16
abietane diterpenoid
A diterpenoid based on an abietane skeleton.
ChEBI ID: 36762
Members (13)
Member | Definition | Role |
---|---|---|
11-hydroxysugiol | An abietane diterpenoid that is sugiol in which the hydrogen ortho to the phenolic hydroxy group has been replaced by a hydroxy group. | 11-hydroxysugiol |
abietic acid | An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18. | abietic acid |
cryptotanshinone | Cryptotanshinone | |
dehydroabietic acid | An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group. | dehydroabietic acid |
dehydroabietinol | dehydroabietadienol | |
Dihydrotanshinone I | Dihydrotanshinone I | |
ferruginol | An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12. | ferruginol |
miltirone | Miltirone | |
podocarpic acid | An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position. | podocarpic acid |
salvin | An abietane diterpenoid that is abieta-8,11,13-triene substituted by hydroxy groups at positions 11 and 12 and a carboxy group at position 20. It is isolated from rosemary (Rosmarinus officinalis) and common sage (Salvia officinalis) and exhibits anti-angiogenic, antineoplastic, antioxidant and anti-HIV activity. | carnosic acid |
sugiol | An abietane diterpenoid that is ferruginol in which the methylene group para to the phenolic hydroxy group has been substituted by an oxo group. | sugiol |
tanshinone | Tanshinone I | |
tanshinone ii a | 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione |
Research
Studies (2,563)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 56 (2.18) | 18.7374 |
1990's | 102 (3.98) | 18.2507 |
2000's | 490 (19.12) | 29.6817 |
2010's | 1,370 (53.45) | 24.3611 |
2020's | 545 (21.26) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 12 (0.41%) | 5.53% |
Reviews | 129 (4.41%) | 6.00% |
Case Studies | 10 (0.34%) | 4.05% |
Observational | 2 (0.07%) | 0.25% |
Other | 2,772 (94.77%) | 84.16% |